131 related articles for article (PubMed ID: 23223624)
1. Human immunodeficiency virus-1 BF intersubtype recombinant viral protein U second α helix plays an important role in viral release and BST-2 degradation.
De Candia C; Espada C; Duette G; Salomón H; Carobene M
J Gen Virol; 2013 Apr; 94(Pt 4):758-766. PubMed ID: 23223624
[TBL] [Abstract][Full Text] [Related]
2. Viral replication is enhanced by an HIV-1 intersubtype recombination-derived Vpu protein.
De Candia C; Espada C; Duette G; Ghiglione Y; Turk G; Salomón H; Carobene M
Virol J; 2010 Oct; 7():259. PubMed ID: 20920359
[TBL] [Abstract][Full Text] [Related]
3. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu.
Rong L; Zhang J; Lu J; Pan Q; Lorgeoux RP; Aloysius C; Guo F; Liu SL; Wainberg MA; Liang C
J Virol; 2009 Aug; 83(15):7536-46. PubMed ID: 19474106
[TBL] [Abstract][Full Text] [Related]
4. Ubiquitination of BST-2 protein by HIV-1 Vpu protein does not require lysine, serine, or threonine residues within the BST-2 cytoplasmic domain.
Gustin JK; Douglas JL; Bai Y; Moses AV
J Biol Chem; 2012 Apr; 287(18):14837-50. PubMed ID: 22383521
[TBL] [Abstract][Full Text] [Related]
5. A comparative mutational analysis of HIV-1 Vpu subtypes B and C for the identification of determinants required to counteract BST-2/Tetherin and enhance viral egress.
Douglas JL; Bai Y; Gustin JK; Moses AV
Virology; 2013 Jul; 441(2):182-96. PubMed ID: 23582304
[TBL] [Abstract][Full Text] [Related]
6. Functional antagonism of rhesus macaque and chimpanzee BST-2 by HIV-1 Vpu is mediated by cytoplasmic domain interactions.
Yoshida T; Koyanagi Y; Strebel K
J Virol; 2013 Dec; 87(24):13825-36. PubMed ID: 24109238
[TBL] [Abstract][Full Text] [Related]
7. Vpu of a Simian Immunodeficiency Virus Isolated from Greater Spot-Nosed Monkey Antagonizes Human BST-2 via Two AxxxxxxxW Motifs.
Yao W; Yoshida T; Hashimoto S; Takeuchi H; Strebel K; Yamaoka S
J Virol; 2020 Jan; 94(2):. PubMed ID: 31666374
[TBL] [Abstract][Full Text] [Related]
8. A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction.
Kueck T; Neil SJ
PLoS Pathog; 2012; 8(3):e1002609. PubMed ID: 22479182
[TBL] [Abstract][Full Text] [Related]
9. Separable determinants of subcellular localization and interaction account for the inability of group O HIV-1 Vpu to counteract tetherin.
Vigan R; Neil SJ
J Virol; 2011 Oct; 85(19):9737-48. PubMed ID: 21775465
[TBL] [Abstract][Full Text] [Related]
10. Differential Vpu-Mediated CD4 and Tetherin Downregulation Functions among Major HIV-1 Group M Subtypes.
Umviligihozo G; Cobarrubias KD; Chandrarathna S; Jin SW; Reddy N; Byakwaga H; Muzoora C; Bwana MB; Lee GQ; Hunt PW; Martin JN; Brumme CJ; Bangsberg DR; Karita E; Allen S; Hunter E; Ndung'u T; Brumme ZL; Brockman MA
J Virol; 2020 Jul; 94(14):. PubMed ID: 32376625
[TBL] [Abstract][Full Text] [Related]
11. The C-Terminal End of HIV-1 Vpu Has a Clade-Specific Determinant That Antagonizes BST-2 and Facilitates Virion Release.
Sharma S; Jafari M; Bangar A; William K; Guatelli J; Lewinski MK
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867310
[TBL] [Abstract][Full Text] [Related]
12. βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.
Song YE; Cyburt D; Lucas TM; Gregory DA; Lyddon TD; Johnson MC
Viruses; 2018 Oct; 10(10):. PubMed ID: 30347660
[TBL] [Abstract][Full Text] [Related]
13. Some human immunodeficiency virus type 1 Vpu proteins are able to antagonize macaque BST-2 in vitro and in vivo: Vpu-negative simian-human immunodeficiency viruses are attenuated in vivo.
Shingai M; Yoshida T; Martin MA; Strebel K
J Virol; 2011 Oct; 85(19):9708-15. PubMed ID: 21775449
[TBL] [Abstract][Full Text] [Related]
14. Vpu binds directly to tetherin and displaces it from nascent virions.
McNatt MW; Zang T; Bieniasz PD
PLoS Pathog; 2013; 9(4):e1003299. PubMed ID: 23633949
[TBL] [Abstract][Full Text] [Related]
15. Ion channel activity of HIV-1 Vpu is dispensable for counteraction of CD317.
Bolduan S; Votteler J; Lodermeyer V; Greiner T; Koppensteiner H; Schindler M; Thiel G; Schubert U
Virology; 2011 Jul; 416(1-2):75-85. PubMed ID: 21601230
[TBL] [Abstract][Full Text] [Related]
16. Sites of action of HIV-1 Vpu in BST-2/tetherin downregulation.
Arias JF; Iwabu Y; Tokunaga K
Curr HIV Res; 2012 Jun; 10(4):283-91. PubMed ID: 22524176
[TBL] [Abstract][Full Text] [Related]
17. A small molecule compound IMB-LA inhibits HIV-1 infection by preventing viral Vpu from antagonizing the host restriction factor BST-2.
Mi Z; Ding J; Zhang Q; Zhao J; Ma L; Yu H; Liu Z; Shan G; Li X; Zhou J; Wei T; Zhang L; Guo F; Liang C; Cen S
Sci Rep; 2015 Dec; 5():18499. PubMed ID: 26669976
[TBL] [Abstract][Full Text] [Related]
18. Genetic and phenotypic analyses of sequential vpu alleles from HIV-infected IFN-treated patients.
Vanwalscappel B; Rato S; Perez-Olmeda M; Díez Fuertes F; Casartelli N; Alcami J; Mammano F
Virology; 2017 Jan; 500():247-258. PubMed ID: 27855354
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 Vpu antagonizes BST-2 by interfering mainly with the trafficking of newly synthesized BST-2 to the cell surface.
Dubé M; Paquay C; Roy BB; Bego MG; Mercier J; Cohen EA
Traffic; 2011 Dec; 12(12):1714-29. PubMed ID: 21902775
[TBL] [Abstract][Full Text] [Related]
20. Conserved residues within the HIV-1 Vpu transmembrane-proximal hinge region modulate BST2 binding and antagonism.
Lukhele S; Cohen ÉA
Retrovirology; 2017 Mar; 14(1):18. PubMed ID: 28288652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
